New Long-Acting [ 89 Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c02073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Jonas Wilbs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Global Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark. Hauptthemen laut MEDLINE: Deferoxamine, Positron-Emission Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H2020 Health.
Abstract (Originalsprache)
Positron emission tomography (PET) imaging is used in drug development to noninvasively measure biodistribution and receptor occupancy. Ideally, PET tracers retain target binding and biodistribution properties of the investigated drug. Previously, we developed a zirconium-89 PET tracer based on a long-circulating glucagon-like peptide 1 receptor agonist (GLP-1RA) using desferrioxamine (DFO) as a chelator. Here, we aimed to develop an improved zirconium-89-labeled GLP-1RA with increased molar activity to increase the uptake in low receptor density tissues, such as brain. Furthermore, we aimed at reducing tracer accumulation in the kidneys. Introducing up to four additional Zr-DFOs resulted in higher molar activity and stability, while retaining potency. Branched placement of DFOs was especially beneficial. Tracers with either two or four DFOs had similar biodistribution as the tracer with one DFO in vivo, albeit increased kidney and liver uptake. Reduced kidney accumulation was achieved by introducing an enzymatically cleavable Met-Val-Lys (MVK) linker motif between the chelator and the peptide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark.
- Department of Medical Imaging-Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands.
- Global Drug Discovery, Novo Nordisk A/S, 2760 Måløv, Denmark.
- Digital Science and Innovation, Novo Nordisk A/S, 2760 Måløv, Denmark.
ORCID-Profile: Jonas Wilbs, David Rodríguez, Eduardo Felipe Alves Fernandes, Sandra Heskamp
Förderung
- H2020 Health
Zitieren
APA
Wilbs, J., Raavé, R., Boswinkel, M., Glendorf, T., Rodríguez, D., Fernandes, E. F. A., Heskamp, S., Bjørnsdottir, I., & Gustafsson, M. B. F. (2023). New Long-Acting [ 89 Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c02073
Vancouver
Wilbs J, Raavé R, Boswinkel M, Glendorf T, Rodríguez D, Fernandes EFA, et al. New Long-Acting [ 89 Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c02073
BibTeX
@article{Wilbs2023,
author = {Wilbs, Jonas and Raavé, René and Boswinkel, Milou and Glendorf, Tine and Rodríguez, David and Fernandes, Eduardo Felipe Alves and Heskamp, Sandra and Bjørnsdottir, Inga and Gustafsson, Magnus B F},
title = {New Long-Acting [ 89 Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c02073}
}
EUVIMED